SIETES :: 92637 citas

Resultados de la búsqueda por ERGÓTICOS REFINAR BÚSQUEDA

1.

Lane S, Lynn E, Shakir S. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. BMJ Open 2018;8:e019759. [Ref.ID 102510]

2.

Anónimo. Valvulopathies d'origine médicamenteuse. Prescrire 2013;33:668-72. [Ref.ID 96188]

3.

Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]

4.

Salinas Botrán A, Urgelés Puértolas D, Peregrín Abad E. Psicosis puerperal asociada a cabergolina. Med Clin (Barc) 2013;140:45-6. [Ref.ID 94667]

5.

Anónimo. Traitement de la maladie de Parkinson. Première partie. D'abord une monothérapie para lévodopa ou agoniste dopaminergique. Prescrire 2011;31:200-5. [Ref.ID 90309]

6.

Anónimo. Management of medication overuse headache. BMJ 2010;340:968-72. [Ref.ID 87673]

7.

Abecia JC, García del Pozo J, de Abajo FJ. Utilización de antimigrañosos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-5. [Ref.ID 86456]

8.

Anónimo. Rotigotine et jambes sans repos. Le pire des agonistes dopaminergiques. Prescrire 2009;29:331. [Ref.ID 85781]

9.

Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now?. Lancet 2005;366:409-21. [Ref.ID 84295]

10.

Oransky I. Albert Hofmann. Lancet 2008;371:2168. [Ref.ID 83427]

11.

Baxter K, Sharp JM. Adverse drug interactions. Adv Drug React Bull 2008;248:951-4. [Ref.ID 82877]

12.

Thanacoody RHK. Serotonin syndrome. Adv Drug React Bull 2007;243:931-4. [Ref.ID 81222]

13.

Bánhidy F, Ács N, Puhó E, Czeizel AE. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth. Br J Clin Pharmacol 2007;64:510-6. [Ref.ID 81177]

14.

Roth BL. Dopamine agonists and valvular heart disease. Dr. Roth replies. N Engl J Med 2007;356:1679-80. [Ref.ID 79842]

15.

Zanettini R, Pezzoli G. Dopamine agonists and valvular heart disease. Drs. Zanetini and Pezzoli reply. N Engl J Med 2007;356:1678-9. [Ref.ID 79841]

16.

Schade R, Andersohn F, Garbe E. Dopamine agonists and valvular heart disease. Dr. Schade and colleagues reply. N Engl J Med 2007;356:1678. [Ref.ID 79840]

17.

Sartiani L, Cerbai E, Mugelli A. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677-8. [Ref.ID 79839]

18.

Ziegler JL, Bukhman GY. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677. [Ref.ID 79838]

19.

Kast RE, Altschuler EL. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1677. [Ref.ID 79837]

20.

Linkova H, Ruzicka E, Penicka M. Dopamine agonists and valvular heart disease. N Engl J Med 2007;356:1676. [Ref.ID 79836]